Jakafi and Retinal detachment - a phase IV clinical study of FDA data

Summary:

Retinal detachment is reported as a side effect among people who take Jakafi (ruxolitinib phosphate), especially for people who are female, have been taking the drug for < 1 month also take Magnesium, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Retinal detachment when taking Jakafi. It is created by eHealthMe based on reports of 56,447 people who have side effects when taking Jakafi from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Retinal detachment?

Retinal detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue) is found to be associated with 712 drugs and 1,007 conditions by eHealthMe. Check the latest studies of Retinal detachment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

56,447 people reported to have side effects when taking Jakafi.
Among them, 23 people (0.04%) have Retinal detachment.

Among these 23 people:

How long have people been on Jakafi when they have Retinal detachment? *

What is the gender of people who have Retinal detachment when taking Jakafi? *

female: 75 %
male: 25 %

What are other drugs people take besides Jakafi? *

What are other side effects people have besides Retinal detachment? *

Abdominal Discomfort: 8 people, 34.78%
Mobility Decreased (ability to move is reduced): 8 people, 34.78%
Pain In Extremity: 7 people, 30.43%
Onychoclasis (breaking of the nails): 7 people, 30.43%
Neck Mass (mass in neck): 7 people, 30.43%
Memory Loss: 7 people, 30.43%
High Blood Cholesterol: 7 people, 30.43%
Hepatic Steatosis (fatty liver disease): 7 people, 30.43%
Hair Texture Abnormal: 7 people, 30.43%
Gastric Ulcer (stomach ulcer): 7 people, 30.43%

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 9 people, 39.13%
Dizziness: 3 people, 13.04%
Stress And Anxiety: 2 people, 8.70%
Essential Thrombocythaemia (chronic blood cancer): 2 people, 8.70%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 8.70%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 8.70%
Hypersensitivity: 1 person, 4.35%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Retinal detachment?

- Check whether Retinal detachment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Jakafi:

Jakafi (56,530 reports)

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinal detachment:

Retinal detachment (712 drugs)

Browse all the conditions that are associated with Retinal detachment:

Retinal detachment (1,007 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.